Syndax Pharmaceuticals SNDX Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's amortization expense related to capitalized debt issuance costs?
- Syndax Pharmaceuticals (SNDX) reported amortization expense related to capitalized debt issuance costs of $56K in Q1 2026.
- How has Syndax Pharmaceuticals's amortization expense related to capitalized debt issuance costs changed year-over-year?
- Syndax Pharmaceuticals's amortization expense related to capitalized debt issuance costs decreased by 50.0% year-over-year, from $112K to $56K.